Evolus, Inc. Common Stock (EOLS)
PHARMACEUTICAL PREPARATIONS
Evolus, Inc. Common Stock (EOLS) is listed on Nasdaq, where it has traded since February 8, 2018.
- Listed On
- Nasdaq
- Listed Since
- February 8, 2018
- Employees
- 353
- Market Cap
- $504M
About Evolus, Inc. Common Stock
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 155 institutions reported holding EOLS, with 48.3 million shares worth $335.1 million in aggregate. The largest reported holder was Nantahala Capital Management, with 5.6 million shares worth $38.9 million. Of the 5 largest holders listed below, 2 added shares, 2 reduced their positions and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Nantahala Capital Management | 5,602,021 | $39M | Reduced 12.15% |
| BlackRock | 4,840,828 | $34M | Added 12.83% |
| Vanguard | 3,391,704 | $24M | Reduced 0.22% |
| Braidwell | 3,155,209 | $22M | Added 1.61% |
| Frazier Life Sciences Management | 2,630,665 | $18M | Unchanged |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is EOLS?
Evolus, Inc. Common Stock (EOLS) is listed on Nasdaq, where it has traded since February 8, 2018.
Who are the largest institutional holders of EOLS?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of EOLS were Nantahala Capital Management, BlackRock and Vanguard.
How many institutions own EOLS?
155 institutions reported a position in EOLS for the quarter ended June 30, 2026, worth $335.1 million in total.
Did institutions buy or sell EOLS last quarter?
Of the 5 largest reported holders, 2 added shares, 2 reduced their positions and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for EOLS.
Every reported institutional holder, plus insider and congressional trades in EOLS, on SentiSense.